×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CTMX – cytomx therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CTMX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/14
06:08 am
ctmx
CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress [Yahoo! Finance]
Medium
Report
CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress [Yahoo! Finance]
4/6
05:41 pm
ctmx
CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment [Yahoo! Finance]
Medium
Report
CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment [Yahoo! Finance]
3/27
06:14 pm
ctmx
CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress [Yahoo! Finance]
Low
Report
CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress [Yahoo! Finance]
3/23
01:04 pm
ctmx
CytomX Therapeutics (CTMX) had its price target raised by Piper Sandler from $10.00 to $12.00. They now have an "overweight" rating on the stock.
Low
Report
CytomX Therapeutics (CTMX) had its price target raised by Piper Sandler from $10.00 to $12.00. They now have an "overweight" rating on the stock.
3/20
09:28 pm
ctmx
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results [Yahoo! Finance]
Low
Report
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results [Yahoo! Finance]
3/20
06:39 pm
ctmx
CytomX Therapeutics (CTMX) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d)".
Low
Report
CytomX Therapeutics (CTMX) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d)".
3/19
10:44 am
ctmx
CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.
Low
Report
CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.
3/18
02:07 pm
ctmx
CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:10 pm
CTMX
cytomx therapeutics, inc.
MISS
Report
-8.4%
cytomx therapeutics, inc.
5/12/2025
06:15 am
CTMX
cytomx therapeutics, inc.
BEAT
Report
71.8%
cytomx therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/16
04:10 pm
ctmx
Form SCHEDULE 13G CytomX Therapeutics, Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G CytomX Therapeutics, Filed by: Point72 Asset Management, L.P.
3/26
05:40 pm
ctmx
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: VANGUARD GROUP INC
3/19
06:41 pm
ctmx
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Chu Yu-Waye
Medium
Report
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Chu Yu-Waye
3/19
06:35 pm
ctmx
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: McCarthy Sean A.
Medium
Report
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: McCarthy Sean A.
3/19
06:25 pm
ctmx
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: BELVIN MARCIA
Medium
Report
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: BELVIN MARCIA
3/19
06:21 pm
ctmx
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Ogden Christopher
Medium
Report
Form 4 CytomX Therapeutics, For: Mar 17 Filed by: Ogden Christopher
3/19
04:06 pm
ctmx
Form 8-K CytomX Therapeutics, For: Mar 17
Medium
Report
Form 8-K CytomX Therapeutics, For: Mar 17
3/18
04:07 pm
ctmx
Form 424B5 CytomX Therapeutics,
Medium
Report
Form 424B5 CytomX Therapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER
32.5%
3/16 CytomX Therapeutics Announces New Employment Inducement Grant 27.7%
4/28 CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors 25.3%
11/19 CytomX Therapeutics Inc (NASDAQ: CTMX) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 15.1%
3/30 CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline 14.5%
5/9 Form 10-Q CytomX Therapeutics, For: Mar 31 11.0%
7/9 CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration 9.3%
2/7 CytomX Therapeutics Announces New Employment Inducement Grant 8.6%
12/19 CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook 8.4%
8/6 CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 8.4%
3/16 CytomX Therapeutics Announces New Employment Inducement Grant 27.7%
4/28 CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors 25.3%
11/19 CytomX Therapeutics Inc (NASDAQ: CTMX) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 15.1%
3/30 CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline 14.5%
5/9 Form 10-Q CytomX Therapeutics, For: Mar 31 11.0%
7/9 CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration 9.3%
2/7 CytomX Therapeutics Announces New Employment Inducement Grant 8.6%
12/19 CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook 8.4%
8/6 CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 8.4%
TOP News Decliners
3/6
Form SC 13G CytomX Therapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P
-11.6%
4/30 CytomX Therapeutics Inc (NASDAQ: CTMX) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock. -8.3%
5/29 Form 8-K CytomX Therapeutics, For: May 22 -8.2%
8/8 CytomX Therapeutics Inc (NASDAQ: CTMX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.6%
10/24 CytomX Therapeutics to Announce Third Quarter 2019 Financial Results -6.9%
11/11 CytomX Therapeutics Inc (NASDAQ: CTMX) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $25.00. -6.7%
2/28 CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
6/21 Form 8-K/A CytomX Therapeutics, For: Dec 19 -5.7%
8/22 Form 8-K CytomX Therapeutics, For: Aug 19 -4.3%
8/27 CytomX Therapeutics Inc (NASDAQ: CTMX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.1%
4/30 CytomX Therapeutics Inc (NASDAQ: CTMX) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock. -8.3%
5/29 Form 8-K CytomX Therapeutics, For: May 22 -8.2%
8/8 CytomX Therapeutics Inc (NASDAQ: CTMX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.6%
10/24 CytomX Therapeutics to Announce Third Quarter 2019 Financial Results -6.9%
11/11 CytomX Therapeutics Inc (NASDAQ: CTMX) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $25.00. -6.7%
2/28 CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
6/21 Form 8-K/A CytomX Therapeutics, For: Dec 19 -5.7%
8/22 Form 8-K CytomX Therapeutics, For: Aug 19 -4.3%
8/27 CytomX Therapeutics Inc (NASDAQ: CTMX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: